eking behaviors, including over-eating, said Stephen Hurst, Savant HWP Chairman and CEO.Years of preclinical research using a variety of addiction models, by Savant's scientific founder, Stanley Glick, Director of the Center for Neuropharmacology and Neuroscience at Albany Medical College, suggests this compound has the potential to bring a major treatment advance to the fields of addiction med